Coave Therapeutics

Rodolphe Clerval, CEO

April 13 | 1:30pm | BioCentriq Ballroom 

Paris, France


Coave Therapeutics is a genetic medicine company leading the transition of gene therapy from (ultra) rare to prevalent conditions, with an initial focus on neurodegenerative diseases. Coave’s proprietary ALIGATER™ (AAV-Ligand Conjugate) platform introduces chemical modifications to AAV capsids, overcoming the limitations of current vectors on efficacy, safety, and manufacturability. With low doses and optimized routes of administration, our conjugated AAV vectors have demonstrated markedly improved transduction and biodistribution in the central nervous system and the eye across different species. Coave develops a diversified pipeline of novel genetic medicines that can potentially transform the lives of people afflicted by rare and prevalent neurodegenerative and ocular diseases – including genetically (GBA1-Parkinson, PDE6b-IRD) and non-genetically defined indications (MSA, ALS). Coave Therapeutics is backed by leading international life sciences investors.

By using this website you agree to accept our Privacy Policy and Terms & Conditions